Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) have been given a consensus rating of “Hold” by the twenty-three brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $17.74.

Several brokerages recently commented on VRX. Cantor Fitzgerald set a $23.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Tuesday. Piper Jaffray Companies set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a report on Wednesday, August 9th. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a report on Wednesday, August 9th. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a report on Thursday, August 10th. Finally, Wells Fargo & Company reaffirmed a “sell” rating on shares of Valeant Pharmaceuticals International in a report on Friday, October 27th.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Receives Average Recommendation of “Hold” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/01/valeant-pharmaceuticals-international-inc-vrx-receives-average-recommendation-of-hold-from-analysts.html.

Shares of Valeant Pharmaceuticals International (NYSE VRX) opened at 11.69 on Wednesday. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $23.32. The company’s market capitalization is $4.07 billion. The firm’s 50-day moving average is $13.47 and its 200-day moving average is $13.73.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. Valeant Pharmaceuticals International’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.88) EPS. On average, equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

In related news, Director Schutter Richard U. De acquired 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the transaction, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.87% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Holdings Inc. increased its position in Valeant Pharmaceuticals International by 2.9% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock worth $8,509,000 after purchasing an additional 13,810 shares in the last quarter. Morgan Stanley increased its position in Valeant Pharmaceuticals International by 48.2% during the 1st quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock worth $30,631,000 after purchasing an additional 903,256 shares in the last quarter. Legal & General Group Plc increased its position in Valeant Pharmaceuticals International by 9.2% during the 2nd quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock worth $23,895,000 after purchasing an additional 121,032 shares in the last quarter. Paloma Partners Management Co increased its position in Valeant Pharmaceuticals International by 12.0% during the 1st quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock worth $310,000 after purchasing an additional 2,996 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Valeant Pharmaceuticals International by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock worth $76,990,000 after purchasing an additional 621,618 shares in the last quarter. Institutional investors and hedge funds own 50.21% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.